Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04057001 · ClinicalTrials.gov registry record
Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study
A clinical trial, sponsored by Yale University.
- Terminated
- Registry status
- 49
- Enrollment target
NCT04057001: Clinical Trial study, sponsored by Yale University.
NCT04057001 is a clinical trial that was terminated before completion, run by Yale University. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04057001 was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- 49 participants
- Enrollment target
Study Summary
Compare wait list mortality and time to liver, heart or kidney transplant for registrants listed to consider allografts from Hepatitis C Virus (HCV) Nucleic Amplification Testing (NAT)+ donors versus those who are not . The umbrella protocol has been set up to include heart and kidney transplant recipients.
Primary Outcome
Number of days between date of adding patient to the waitlist and transplant date comparing waitlist registrants listed to accept HCV NAT+ donor organs with those followed per standard of care (not accepting HCV NAT+ donor organs).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2023-03-06 |
Why NCT04057001 stopped before completion
NCT04057001 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 49 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04057001 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04057001 about?
NCT04057001 is a clinical study titled "Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study". Compare wait list mortality and time to liver, heart or kidney transplant for registrants listed to consider allografts from Hepatitis C Virus (HCV) Nucleic Amplification Testing (NAT)+ donors versus those who are not . The umbrella protocol has been set up to include heart and kidney transplant rec...
What is the current status of trial NCT04057001?
This trial is currently terminated. The enrollment target is 49 participants. The study started on 2019-07-01. Estimated completion is 2023-03-06.
Who is sponsoring clinical trial NCT04057001?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI